Gene Therapy-vMCO-010 for Stargardt Disease

Phase-Based Progress Estimates
Nanoscope Clinical Site, Miami, FL
Stargardt Disease+3 More
Gene Therapy-vMCO-010 - Biological
Any Age
All Sexes
What conditions do you have?

Study Summary

The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease

Eligible Conditions

  • Stargardt Disease
  • Stargardt's disease

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Stargardt Disease

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 48 Weeks

48 Weeks
Effect of vMCO-010 on Light-guided Mobility
Effect of vMCO-010 on determination of optical flow
Effect of vMCO-010 on determination of shape
48 weeks
Effect of vMCO-010 as assessed by visual acuity
Type, severity, and incidence of ocular and systemic adverse events (AEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Stargardt Disease

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

6 Total Participants · 1 Treatment Group

Primary Treatment: Gene Therapy-vMCO-010 · No Placebo Group · Phase 2

Experimental Group · 1 Intervention: Gene Therapy-vMCO-010 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks
Closest Location: Nanoscope Clinical Site · Miami, FL
Photo of Miami 1Photo of Miami 2Photo of Miami 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Stargardt Disease
0 CompletedClinical Trials

Who is running the clinical trial?

Nanoscope Therapeutics Inc.Lead Sponsor
2 Previous Clinical Trials
38 Total Patients Enrolled
Aaron Osborne, MDStudy DirectorNanoscope Therapeutics Inc.

Eligibility Criteria

Age Any Age · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are 16 years of age or older.
You have Stargardt disease or a genetic variant in ABCA4, ELOVL4, or PROM1.
In the study eye: BCVA no better than 20/200 in the fellow eye.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.